Trumenba + hepatitis A vaccine

This entry refers to the co-administration of Pfizer's **Trumenba** (a bivalent recombinant lipoprotein 2086 vaccine) and a pediatric **hepatitis A vaccine**. Trumenba is designed to prevent invasive disease caused by *Neisseria meningitidis* serogroup B by inducing bactericidal antibodies against factor H binding protein (fHBP), a surface protein that allows the bacteria to evade the host's immune system. The hepatitis A vaccine is an inactivated virus vaccine that provides active immunity against the hepatitis A virus (HAV). This specific co-administration regimen has been evaluated in Phase 2 clinical trials (such as NCT01461980) to assess the safety, tolerability, and immunogenicity of Trumenba when given alongside routine pediatric vaccinations in healthy toddlers aged 12 to 24 months.

Other names

Bivalent rLP2086Neisseria meningitidis serogroup B bivalent recombinant lipoprotein 2086 vaccine